Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on blood transfusion safety and pathogen-protected blood components. These filings offer detailed information on the company’s financial performance, business risks, and corporate governance.
Investors can review current reports on Form 8-K, which Cerus uses to furnish press releases announcing quarterly financial results, such as second and third quarter 2025 earnings. These 8-K filings summarize product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, government contract revenue related to INTERCEPT RBC and other development programs, and updates to annual product revenue guidance.
Cerus’ periodic reports on Form 10-K and Form 10-Q, referenced in company press releases, include sections such as “Risk Factors” that discuss uncertainties related to commercialization of the INTERCEPT Blood System, regulatory approvals for the INTERCEPT RBC system, development of technologies like INT200 and lyophilized IFC, supply chain considerations, and macroeconomic and geopolitical risks.
Through this page, users can also monitor disclosures about board and leadership changes, such as those reported in Form 8-K filings covering director retirements and appointments of new board leadership roles. These documents provide context on the company’s governance structure.
Stock Titan enhances these filings with AI-powered tools that summarize lengthy documents, highlight key items such as revenue trends, development program updates, and risk factor changes, and help readers navigate complex regulatory language. Users can quickly locate information on topics like product revenue composition, government contract funding, and the status of clinical and regulatory programs related to Cerus’ INTERCEPT technologies.
Cerus Corp Chief Legal Officer Chrystal Jensen reported an open-market sale of 113,008 shares of Common Stock on
According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1 to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of restricted stock units, and are described as not a discretionary sale. Following the transactions, Jensen directly holds 946,131 shares of Cerus common stock.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported an open‑market sale of 165,200 shares of common stock on March 12, 2026 at a weighted average price of $1.6572 per share. According to the filing, the sale was executed under an instruction intended to comply with Rule 10b5‑1 and was made to cover statutory tax withholding obligations and related brokerage fees arising from the vesting of restricted stock units, rather than as a discretionary sale. After this transaction, he directly holds 1,747,674 shares of Cerus common stock.
CERUS CORP President and CEO William Mariner Greenman reported an open-market sale of 447,757 shares of common stock on March 12, 2026 at a weighted average price of
Cerus Corporation’s Chief Financial Officer Kevin Dennis Green reported an open-market sale of 127,544 shares of Common Stock at a weighted average price of $1.6572 per share. According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1.
The filing explains the sale was elected on the date of grant to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of certain restricted stock units, and is not a discretionary sale by the CFO. After this transaction, he directly holds 1,040,551 shares of Cerus common stock.
CERUS CORP Chief Medical Officer Benjamin Richard J reported an open-market sale of 101,740 shares of Common Stock at a weighted average price of $1.6572 per share. After this transaction, he directly holds 777,361 shares.
According to the footnotes, these shares were sold under an instruction intended to comply with Rule 10b5-1 that was elected on the grant date to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of restricted stock units, and are described as not a discretionary sale. The sales occurred in multiple trades at prices ranging from $1.62 to $1.73 per share.
Cerus Corporation has appointed Vivek Jayaraman, currently Chief Operating Officer, as its next President and Chief Executive Officer effective July 1, 2026. On that date, current CEO and Board Chair William “Obi” Greenman will transition to the role of Executive Chairman, and Jayaraman will join the Board.
Under a new letter agreement effective March 11, 2026, Jayaraman will receive an annual base salary of $740,000, a target annual bonus opportunity of up to 80% of base salary starting in 2027, and will be eligible for equity incentives. These include a promotion equity award with a target value of $2,000,000 (75% time-based and 25% performance-based restricted stock units) and a one-time promotional performance-based award with a target value of $1,000,000. The number of shares for these awards will be based on the 30-day average closing price of Cerus common stock, but not less than $2.50 per share for calculation purposes.
If Jayaraman is terminated without cause or resigns for good reason, he may receive 12 months of base salary, a prorated annual bonus in certain cases, up to 12 months of COBRA premium support or equivalent cash payments, and full vesting of unvested time-based and performance-based restricted stock units, including in connection with a qualifying change in control.
CERUS CORP’s Chief Medical Officer Benjamin Richard J reported a mix of stock awards and planned sales. On March 5, 2026, he acquired 55,220 shares of common stock as a grant or award at no cost, increasing his direct holdings.
He then reported selling a total of 125,894 common shares in open-market transactions on March 5, 6, and 9, 2026 at weighted average prices of about $2.06, $2.01, and $1.88 per share. Footnotes state these sales were made under a Rule 10b5-1 trading plan and instructions elected on the grant date to cover statutory tax withholding and related fees, and are described as non-discretionary. After these transactions, he directly owns 879,101 Cerus common shares.
Cerus Corp’s chief financial officer Kevin Dennis Green reported a mix of stock awards and sales. On March 5, 2026, he acquired 63,854 shares of common stock in a grant or award at $0.00 per share, increasing his direct holdings.
On March 5 and 6, 2026, he sold a total of 83,021 shares of common stock in open‑market transactions at weighted average prices of about $2.06 and $2.01 per share. The filing notes that some sales were made under a Rule 10b5‑1 trading plan and that certain shares were sold pursuant to instructions elected at grant solely to cover statutory tax withholding and related brokerage fees, described as not discretionary sales.
After these transactions, Green directly owned 1,168,095 shares of Cerus common stock.
Cerus Corp Chief Medical Officer Benjamin Richard reported multiple stock transactions in early
Cerus Corp Chief Legal Officer Chrystal Jensen reported two stock transactions. On March 5, 2026, Jensen acquired 55,220 shares of common stock as a grant or award at $0.00 per share, bringing direct holdings to 1,083,514 shares. On March 6, 2026, Jensen sold 30,845 shares of common stock at a weighted average price of $2.0055 per share, leaving 1,059,139 shares directly owned. The sale was executed under a Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees related to vesting restricted stock units and was not a discretionary sale.